Wedbush Maintains Outperform on Aclaris Therapeutics, Lowers Price Target to $8
Benzinga Newsdesk 3 days ago
Analyst RatingsNewsPrice Target
Wedbush analyst Martin Fan maintains Aclaris Therapeutics (NASDAQ:ACRS) with a Outperform and lowers the price target from $10 to $8.
Wedbush analyst Martin Fan maintains Aclaris Therapeutics (NASDAQ:ACRS) with a Outperform and lowers the price target from $10 to $8.